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Abstract
Background
Observational studies have demonstrated an association between decreased vitamin D
level and risk of multiple sclerosis (MS); however, it remains unclear whether this relation-
ship is causal. We undertook a Mendelian randomization (MR) study to evaluate whether
genetically lowered vitamin D level influences the risk of MS.
Methods and Findings
We identified single nucleotide polymorphisms (SNPs) associated with 25-hydroxyvitamin
D (25OHD) level from SUNLIGHT, the largest (n = 33,996) genome-wide association study
to date for vitamin D. Four SNPs were genome-wide significant for 25OHD level (p-values
ranging from 6 × 10−10 to 2 × 10−109), and all four SNPs lay in, or near, genes strongly impli-
cated in separate mechanisms influencing 25OHD. We then ascertained their effect on
25OHD level in 2,347 participants from a population-based cohort, the Canadian Multicen-
tre Osteoporosis Study, and tested the extent to which the 25OHD-decreasing alleles
explained variation in 25OHD level. We found that the count of 25OHD-decreasing alleles
across these four SNPs was strongly associated with lower 25OHD level (n = 2,347, F-test
statistic = 49.7, p = 2.4 × 10−12). Next, we conducted an MR study to describe the effect of
genetically lowered 25OHD on the odds of MS in the International Multiple Sclerosis Genet-
ics Consortium study, the largest genetic association study to date for MS (including up to
14,498 cases and 24,091 healthy controls). Alleles were weighted by their relative effect
on 25OHD level, and sensitivity analyses were performed to test MR assumptions. MR
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analyses found that each genetically determined one-standard-deviation decrease in log-
transformed 25OHD level conferred a 2.0-fold increase in the odds of MS (95% CI: 1.7–2.5;
p = 7.7 × 10−12; I2 = 63%, 95% CI: 0%–88%). This result persisted in sensitivity analyses
excluding SNPs possibly influenced by population stratification or pleiotropy (odds ratio
[OR] = 1.7, 95% CI: 1.3–2.2; p = 2.3 × 10−5; I2 = 47%, 95% CI: 0%–85%) and including
only SNPs involved in 25OHD synthesis or metabolism (ORsynthesis = 2.1, 95% CI: 1.6–2.6,
p = 1 × 10−9; ORmetabolism = 1.9, 95% CI: 1.3–2.7, p = 0.002). While these sensitivity analy-
ses decreased the possibility that pleiotropy may have biased the results, residual pleiot-
ropy is difficult to exclude entirely.
Conclusions
A genetically lowered 25OHD level is strongly associated with increased susceptibility to
MS. Whether vitamin D sufficiency can delay, or prevent, MS onset merits further investiga-
tion in long-term randomized controlled trials.
Introduction
Multiple sclerosis (MS) is the most common permanent neurological disorder affecting young
adults [1]. It is a debilitating autoimmune condition that presents early in life, with a mean age
of onset of 28–31 y. Epidemiological studies have indicated that the prevalence of MS varies
geographically, such that regions of higher latitude and with decreased levels of sunlight expo-
sure have a higher prevalence of MS [2,3]. Since the circulating level of vitamin D, as measured
by the level of 25-hydroxyvitamin D (25OHD, the clinical determinant of vitamin D status), is
partially derived from sunlight exposure, it has been suggested that 25OHD deficiency may be
the causal risk factor mediating this latitudinal gradient [4]. Further evidence to support the
vitamin D hypothesis arose from the Nurses’Health Study, which reported a protective effect
on MS for women who had high levels of daily vitamin D intake [5]. Lower vitamin D level has
also been associated with higher rates of MS relapse [6] and higher MS-specific disease activity
and disability [7]. Vitamin D has important effects upon the immune system, and its immune-
modulating effects have been observed in multiple cell-culture experiments [8], providing pos-
sible biological mechanisms whereby vitamin D may influence MS risk.
To date, there has been one published meta-analysis investigating the effect of vitamin D
supplementation on MS relapse; the meta-analysis included five randomized controlled trials
(RCTs) with a total of 254 participants [9]. The authors reported that the effect of high-dose
vitamin D treatment on MS relapse was inconclusive (odds ratio [OR] = 0.98, 95% CI: 0.45–
2.16) and that these trials had important methodological limitations, such as small sample size
and short duration of vitamin D treatment. In contrast, two non-blinded trials demonstrated
improved clinical outcomes with vitamin D therapy; however, disease activity or MRI changes
were not the primary outcome of these trials [10,11]. Importantly, all of these trials test whether
vitamin D can treatMS, but provide no insight into whether vitamin D can preventMS.
Consequently, clinical practice guidelines for the treatment of MS [12] do not include vita-
min D therapy. This is at least partially attributable to the possibility of confounding in the
above observational studies. Additionally, observational studies are prone to reverse causation,
where, for example, individuals with MS may spend less time outdoors and may as a result
have lower circulating 25OHD levels. However, if decreased 25OHD levels are causally
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associated with MS, this could have important implications since vitamin D insufficiency,
defined as 25OHD level< 50 nmol/l, is common and increasing in prevalence. This was
observed in the National Health and Nutrition Examination Survey (NHANES): in 2005,
41.6% of adult Americans were found to be vitamin D insufficient, and mean 25OHD level
decreased from 75 nmol/l in 1988 to 50 nmol/l in 2006 [13,14].
In the absence of high-quality RCT data, the principles of Mendelian randomization (MR)
can be applied to strengthen or refute the causality of biomarkers in disease etiology [15]. MR
analysis uses genetic associations to test the effects of biomarkers, such as 25OHD, on the risk
of disease. This approach, which is conceptually similar to an RCT, is based on the principle
that genetic variants are randomly allocated at meiosis, and consequently these genetic variants
are independent of many factors that bias observational studies, such as confounding and
reverse causation. MR methods have been used previously to investigate the role of high-den-
sity lipoprotein [16] and C-reactive protein [17] in predisposition to cardiovascular disease,
and have provided strong evidence that PCSK9 inhibition prevents cardiovascular disease [18].
MR methods may be of particular relevance for understanding the etiology of MS since the
date of disease onset is often poorly recognized clinically and MR studies assess the effect of
lifetime exposures.
Here we adopted an MR design to clarify whether 25OHD level lies in the causal pathway
for MS susceptibility. In order to assess whether a reduced level of 25OHD is associated with
an increased risk of MS, we selected genome-wide significant single nucleotide polymorphisms
(SNPs) as identified by SUNLIGHT (Study of Underlying Genetic Determinants of Vitamin D
and Highly Related Traits), the largest genome-wide association study (GWAS) published to
date for 25OHD level. Next, we estimated the effect of each of these SNPs upon 25OHD level
in the Canadian Multicentre Osteoporosis Study (CaMos) and tested their validity as instru-
mental variables for MR analyses. Finally, we applied the principles of MR to investigate the
association of a lifetime of genetically lowered 25OHD level with MS risk using data from the
International Multiple Sclerosis Genetics Consortium (IMSGC).
Methods
SNP Selection and Data Sources
Genetic variants associated with 25OHD level at a genome-wide significant level (p< 5 × 10−8)
were obtained from SUNLIGHT [19], a GWAS consisting of 33,996 individuals of European
descent from 15 cohorts. 25OHD level in this study was measured by radioimmunoassay,
chemiluminescent assay, ELISA, or mass spectrometry. Given that different cohorts used dif-
ferent methods to measure 25OHD level, results were combined across cohorts in SUNLIGHT
using Z-score-weighted meta-analysis.
CaMos was used to estimate the effect of each genome-wide significant SNP on 25OHD
level, since the effect of each SNP upon 25OHD level could not be used from SUNLIGHT,
because of the Z-score meta-analytic approach employed [20]. CaMos is a large population-
based cohort and was among the largest included in the replication phase of SUNLIGHT. It
includes 2,347 individuals who were genotyped using TaqMan genotyping at the same
genome-wide significant vitamin D loci found in SUNLIGHT.
To obtain precise estimates for the association of 25OHD with MS, we tested the effect of
each genome-wide significant SNP for vitamin D level in the IMSGC Immunochip study, the
largest international genetic study of MS, involving 14,498 MS cases and 24,091 healthy con-
trols [21]. All participants were of European ancestry and were genotyped using the Immuno-
chip array, which is a custom array designed to interrogate SNPs with potential immune
system effects. Cases were defined as individuals diagnosed by a neurologist according to
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recognized diagnostic criteria dependent on laboratory and clinical information [22–24].
When data were not available for a specific SNP in the IMSGC Immunochip study, we used
data from the second largest MS genetic study, the IMSGC study and IMSGC/Wellcome Trust
Case Control Consortium 2 (IMSGC/WTCCC2) study, which included 9,772 cases and 6,332
controls taken from the IMSGC/WTCCC2 common control set [25].
SNP Validation and Effect Sizes
Linkage disequilibrium assessment. One requirement of MR studies is that the selected
SNPs must not be in linkage disequilibrium (LD) since if a selected SNP is highly correlated
with other risk factor loci, this may result in confounding [15]. In order to verify that the SNPs
in this study met this requirement, we measured LD between all selected SNPs using CEU sam-
ples from the 1000 Genomes Project (n = 94) [26].
Pleiotropy assessment. MR analyses assume that the chosen SNPs do not exert pleiotropic
effects on the outcome (in this case, MS) by operating through biological pathways indepen-
dent of the exposure (in this case, 25OHD level). However, in MR, a SNP may influence the
outcome via other factors if the SNP acts upon the other factors through the exposure itself
[27]. Previous work has assessed possible pleiotropic actions of the 25OHD-related SNPs used
in our analysis by investigating the association between 25OHD-related SNPs and clinical traits
in the 1958 British Birth Cohort, which included 6,877 participants of European descent [28].
In this cohort, no associations were found between these SNPs and relevant potential pleiotro-
pic pathways, such as sun exposure, time outside, physical activity, oily fish consumption,
smoking, alcohol consumption, body mass index (BMI), abdominal obesity, or social class (p
> 0.05 for all) [28]. However, we note that some of these factors, such as sun exposure, time
outside, BMI, and abdominal obesity, could act at least partially through the vitamin D path-
way. Furthermore, SNPs associated with 25OHD level did not associate with other biomarkers
(including C-reactive protein, IgE level, von Willebrand factor, tissue plasminogen activator,
D-dimer, fibrinogen, triglyceride level, high-density lipoprotein, low-density lipoprotein, total
cholesterol, forced expiratory volume, diastolic blood pressure, IGF-1, and HbA1c), and no
interactions were observed between the SNPs, biomarkers, and 25OHD level. Additional
details are provided in S1 Table.
To further explore sources of pleiotropy, we also conducted a systematic literature search of
gene name, gene mutation, and protein name to examine the published literature for possible
pleiotropic mechanisms for any of our selected SNPs for effects on MS and autoimmunity
using PubMed. Details of this method are described in S1 Methods.
Population stratification assessment. The 1958 British Birth Cohort has previously
assessed the potential for population stratification of the 25OHD-associated SNPs, which is a
potential source of bias in MR studies since differences in minor allele frequencies between
populations may cause the SNP to be associated with both the ancestry and the outcome [28].
In the 1958 British Birth Cohort, each SNP was tested for association with geographic region,
which was dichotomized as south and middle UK (southeast England, southwest England,
greater London, East Anglia, Midlands, and Wales) versus northern England (north England,
northwest England, Yorkshire, and the Humber) and Scotland. We then further assessed
potential population stratification of each SNP by testing its association with self-declared eth-
nicity in the CaMos cohort and tested the association of each SNP with non-European status,
defined as exclusion from the European cluster in principal component analysis (PCA).
Effect size estimates of SUNLIGHT SNPs upon 25OHD level. To obtain the effect of
each SNP upon 25OHD level, as required for MR analysis, we tested the additive effect of each
minor allele on natural-log-transformed 25OHD level in CaMos, while controlling for sex, age,
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age squared, BMI, and season of 25OHDmeasurement (using categorical variables for summer
[July–September], autumn [October–December], winter [January–March], and spring [April–
June]) [19]. Ethnicity was checked by self-report and verified using PCA. To prevent popula-
tion stratification from confounding our results, individuals who did not cluster with other
Europeans were excluded from this analysis and were not used to measure the effect of each
SNP upon 25OHD. The number of 25OHD-decreasing alleles was calculated for each partici-
pant in the CaMos cohort. This allele count was tested for an association with natural-log-
transformed 25OHD level using linear regression, which had been residualized for the above
covariates, and the F-statistic for the allele score was reported. The multiply adjusted natural-
log-transformed 25OHD level was then assessed for each category of allele count, and a non-
parametric trend test across these allele counts was computed.
Association of SUNLIGHT SNPs with Multiple Sclerosis Susceptibility
In order to increase study power and obtain the most precise estimate of the association of
25OHD-associated SNPs with risk of MS, we used summary-level data from the IMSGC
Immunochip study, if available (as described above). However, the IMSGC Immunochip geno-
typing array used was not genome-wide, so not all SNPs were captured in this experiment. If a
SNP was not included in the IMSGC Immunochip study, then summary statistics from the sec-
ond largest genotyped cohort, the IMSGC/WTCCC2 cohort, were selected. In the event that a
SNP was not genotyped in either cohort, summary statistics for a perfect proxy SNP, defined as
a surrogate SNP with perfect LD (r2 = 1.0) to the SNP interest, were selected. LD for proxy
SNPs was calculated using CEU samples from the 1000 Genomes Project (n = 94) since the
IMSGC samples are of the same ancestry [26]. We then assessed whether each SNP was associ-
ated with the risk of MS, applying a Bonferroni correction, where statistical significance was
declared at p 0.05/n where n is the number of SNPs associated with 25OHD level from
SUNLIGHT.
Mendelian Randomization Estimates
We conducted our MR analysis by assessing the effects of the SNPs upon risk of MS, weighting
the effect of each SNP by the magnitude of its effect upon 25OHD level. In this study design,
which has been described previously [29–31], the independent SNPs evaluate the association of
exposure to genetically lowered 25OHD with MS risk. The individual estimates of the effect
were then pooled using statistically efficient estimators formally analogous to those of inverse-
variance-weighted meta-analysis [32]. We carried out a meta-analysis of estimates obtained
from individual 25OHD-decreasing alleles using both fixed-effects and random-effects models
to obtain pooled estimates for the combined effect of the 25OHD SNPs on MS.
Specifically, let x and y denote the centered and scaled natural-log 25OHD and log-odds MS
traits, respectively, and suppose these are related by the linear structural equation: y = αx + η.
Here, η is a stochastic error term, and in general x and η are correlated because of confounding.
The parameter α quantifies the causal effect of x on y, and is thus the parameter we seek to esti-
mate. Let ui denote the allele dosage variable of the i
th genetic variant. Let γi and βi denote effect
size estimates (derived from GWAS data) of ui on the exposure x (change in natural-log
25OHD level) and outcome y (change in log odds of MS), respectively, and let s(βi) denote the
standard error of βi. Then the MR estimate associated with the i
th genetic variant is αi = βi/γi,
and the variance of this estimate is vi = (s[βi])/γi)
2. Define the precision of the ith MR estimate
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of α by wi = 1/vi. The inverse-variance-weighted fixed-effects estimate is then
afixed ¼
Xn
i¼1
wiai
Xn
i¼1
wi
ð1Þ
and the standard error s(αﬁxed) of this estimate is given by
sðafixedÞ ¼
X
i¼1
wi
 1 2=
We observe that αfixed may also be interpreted as the regression coefficient resulting from
the generalized linear regression of the outcome effect sizes βi on the exposure effect sizes γi
assuming heteroskedastic errors; in this regression, the ith error term has a variance equal to s
(βi)
2, and the offset coefficient in the regression is constrained to be zero.
The random-effects estimate αrandom and its standard error s(αrandom) were also constructed
from the individual estimates using standard methods [33] in which the weights are adjusted
to account for the intrinsic variability (or heterogeneity) in the effect size. Heterogeneity may
be quantified with the parameter I2, which reports the fraction of the total variance in the
meta-analytic estimate that is due to intrinsic variability in the effect size, as distinct from vari-
ability arising from measurement error [34]. The random-effects estimate αrandom and its stan-
dard error s(αrandom) are given by equations analogous to those for αfixed and s(αfixed), in which
the weights assigned to individual estimates are adjusted to take into account heterogeneity in
the effect size.
For all MR meta-analyses, we report estimates using both fixed-effects and random-effects
models. The effect size for each meta-analysis is reported in the main results as the effect of a
one-standard-deviation (1-SD) change in natural-log-transformed 25OHD level, since this
metric is more interpretable than an arbitrary difference. This measure is given by exp(αfixed)
for the fixed-effects model and by exp(αrandom) for the random-effects model. We also report
the I2 as an assessment of heterogeneity.
In order to provide a better clinical interpretation of a 1-SD change in natural-log-trans-
formed 25OHD level, we selected three different clinically relevant 25OHD thresholds for vita-
min D status (<25 nmol/l for vitamin D deficiency,<50 nmol/l for vitamin D insufficiency,
and>75 nmol/l for vitamin D sufficiency) [35]. These thresholds were converted to the natural
log scale because the magnitude of a 1-SD change is not constant on the untransformed scale.
For each of these natural-log-transformed 25OHD levels, we then calculated a 1-SD increase in
natural-log-transformed 25OHD. To obtain 25OHD levels that correspond to circulating levels
in units of nanomoles/liter, we then back-transformed these values.
Sensitivity Analyses
MR estimates were recalculated after exclusion of SNPs potentially influenced by pleiotropy
or population stratification. Since SNPs associated with 25OHD level in SUNLIGHT influence
either 25OHD synthesis or 25OHDmetabolism [28], we elected to perform a stratified MR
analysis where SNPs involved in either 25OHD synthesis or metabolism were analyzed
separately.
(2)
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Results
SNP Selection and Validation
SNP selection. A schematic representation of the MR study design is presented in Fig 1.
SUNLIGHT identified four SNPs as genome-wide significant for 25OHD level [19]. These
included rs2282679 in GC (association with 25OHD: p = 1.9 × 10−109), rs12785878 near
DHCR7 (p = 2.1 × 10−27), rs10741657 near CYP2R1 (p = 3.3 × 10−20), and rs6013897 in
CYP24A1 (p = 6.0 × 10−10). We selected these SNPs for our MR study since all are strongly
associated with 25OHD level and map to genes implicated in the modulation of 25OHD level
through distinct mechanisms [36]. Specifically, GC encodes the vitamin D binding protein
(DBP), a group-specific component of serum globulin. DBP acts as the principal protein carrier
for 25OHD, transporting 80%–90% of 25OHD to target organs [37–39]. The DHCR7 gene
product is known to convert 7-dehydrocholesterol to cholesterol, providing a substrate for vita-
min D production. CYP2R1 is a regulator of 25OHD synthesis through 25-hydroxylation of
vitamin D in the liver, the first activation step [40], and, lastly, CYP24A1 inactivates 1α25
(OH)2D, rendering inactive the active form of vitamin D (Fig 2). Therefore, all SNPs used in
this study map near genes strongly implicated in vitamin D synthesis, transport, or metabo-
lism. Notably, all four SNPs lie in intergenic or intronic regions, and presently the exact effect
of each SNP on these enzymes is unknown. Nevertheless, all SNPs reside near genes strongly
implicated in vitamin D synthesis or metabolism [36].
Linkage disequilibrium and pleiotropy assessment. There was no evidence of LD
between any of the four 25OHD SNPs (all pairwise r2 0.01) in the 1000 Genomes Project
CEU samples. We note that only two of the SNPs, rs10741657 and rs12785878, were located
on the same chromosome, which greatly decreases the risk of confounding by LD. As described
above, none of the four 25OHD SNPs was associated with relevant pleiotropic pathways in the
1958 British Birth Cohort.
Undertaking a literature review for possible pleiotropic pathways, we found no evidence for
pleiotropic mechanisms for the vitamin D metabolism SNPs, rs10741657 (CYP2R1) and
rs6013897 (CYP24A1). For rs2282679 (GC), we found that its encoded protein, DBP, has been
associated with macrophage activation and may modulate T cell response to vitamin D [41].
Elevated DBP levels are found in the cerebrospinal fluid of patients with Alzheimer disease
[42] and MS [43], and have been linked to the progression of MS in rats [44]. It has been
Fig 1. Schematic representation of Mendelian randomization analysis. The leftmost box lists SNPs that
were genome-wide significant for 25OHD level in SUNLIGHT (n = 33,996). The blue arrow represents the
effect of SNPs on multiply adjusted natural-log-transformed 25OHD level using data from CaMos (n = 2,347).
The green arrow represents the causal association of decreased 25OHD level with the risk of MS using data
from the largest genetic association study to date for MS (the IMSGC Immunochip study, up to 14,498 cases
and 24,091 healthy controls).
doi:10.1371/journal.pmed.1001866.g001
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argued that DBP can act independently of vitamin D to produce clinical phenotypes; therefore,
we undertook sensitivity analyses excluding rs2282679 (GC) in our MR analyses. Genetic varia-
tion in DHCR7 appears to cause Smith-Lemli-Opitz syndrome, a clinical phenotype relating to
cholesterol deficiency. Given that a recent study suggested an interdependence of cholesterol
and vitamin D pathways in the etiology of MS [45], we queried the association of rs12785878
in the largest publically available GWAS results for lipids, those of the Global Lipids Genetics
Consortium [46], and found that this SNP was associated with a minimum p-value of 0.043
across all lipid traits, suggesting that the SNP is not strongly associated with cholesterol.
Population stratification assessment. Previous reports from the 1958 British Birth
Cohort demonstrated that rs12785878 (DHCR7) was associated with geographic region [28].
Since rs12785878 is unevenly distributed across geography and the prevalence of MS varies by
geographic location, a potential surrogate for local ancestry [4], we tested whether this SNP
was associated with non-European status in CaMos using PCA. The SNP rs12785878 was
strongly associated with non-European status in the CaMos cohort (p = 2.7 × 10−13). No other
SNP showed any evidence of correlation with non-European status (p> 0.5 for all other
SNPs). Given this possible relationship with population stratification, we undertook MR sensi-
tivity analyses excluding the rs12785878 (DHCR7) variant.
Association of SUNLIGHT SNPs with 25OHD Level
Table 1 displays the four SNPs that achieved genome-wide significance for 25OHD level in SUN-
LIGHT and describes their association with 25OHD [19]. Each of these SNPs explained an impor-
tant proportion of the population-level variance in 25OHD level, as reflected by the F-statistic.
Fig 2. Vitamin D pathway. In blue are the genes containing, or in proximity to, SNPs that were genome-wide
significant for 25OHD level in SUNLIGHT (n = 33,996). The p-values for the association with 25OHD level
were 1.9 × 10−109 forGC, 2.1 × 10−27 for DHCR7, 3.3 × 10−20 for CYP2R1, and 6.0 × 10−10 for CYP24A1. Note
that each gene plays an independent role in modulating the level of 25OHD. Kidney and liver images credit:
https://openclipart.org/.
doi:10.1371/journal.pmed.1001866.g002
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The count of 25OHD-decreasing alleles across these four SNPs was strongly associated lower
25OHD level in the CaMos population, residualized for age, season, sex, and BMI (F-statistic = 49.7,
r2 = 2.44%, p for allelic score = 2.4 × 10−12). Fig 3 shows the mean 25OHD levels for individuals
with increasing counts of 25OHD-decreasing alleles (non-parametric trend test, p = 3.3 × 10−19).
Association of SUNLIGHT SNPs with Multiple Sclerosis Susceptibility
Summary statistics for two of the four 25OHD-associated SNPs (rs10741657 at CYP2R1 and
rs12785878 at DHCR7) and their association with MS were taken from the IMSGC Immuno-
chip study (Table 1). rs12785878 at DHCR7 was not directly genotyped in the IMSGC Immu-
nochip study; however, a perfect proxy for rs12785878, rs4944958, was used (r2 = 1.0 between
rs12785878 and rs4944958 in the 1000 Genomes Project CEU samples). Summary statistics for
the remaining two SNPs (rs6013897 at CYP24A1 and rs2282679 at GC) were taken from the
second largest MS genetic association study, the IMSGC/WTCCC2 study. SNP rs6013897 at
CYP24A1 was not present in the IMSGC/WTCCC2 dataset, and therefore a perfect proxy SNP
for rs6013897, rs17217119, was used (r2 = 1.0 between rs17217119 and rs6013897 from the
1000 Genomes Project CEU samples).
All four 25OHD-decreasing alleles were associated with an increased risk of MS (Table 1).
rs12785878 (DHCR7) achieved genome-wide significance for MS risk, while two 25OHD-decreas-
ing alleles (rs10741657 and rs6013897) were moderately associated with MS risk (p = 3.9 × 10−3
and p = 1.7 × 10−3, respectively). The 25OHD-decreasing allele rs2282679 (allele C) (GC) was not
significantly associated with MS risk (p = 0.062) (Table 1). However, three of the 25OHD-associ-
ated SNPs (rs12785878, rs10741657, and rs6013897) remained associated with MS after a Bonfer-
roni correction for the number of independent SNPs (p 0.05/4 = 0.0125).
Table 1. Characteristics of SNPs used as instrumental variables.
Locus Chromosome 25OHD-
Associated
SNP
25OHD-
Decreasing
Allele
Allele
Frequency
Vitamin D Results MS Results
Effect
on
25OHDa
p-Value for
Association
with
25OHDb
F-Statistic
for
25OHDc
OR (95% CI) for
MS
p-Value for
Association
with MS
Study
CYP2R1 11 rs10741657 C 0.62 −0.052 3.3 × 10−20 18.78 1.05 (1.02–1.09) 3.9 × 10−3 IMSGC
Immunochip
[21]
DHCR7 11 rs12785878 G 0.27 −0.056 2.1 × 10−27 18.29 1.11 (1.07–1.15)d 8.7 × 10−9 IMSGC
Immunochip
[21]
GC 4 rs2282679 C 0.30 −0.047 1.9 × 10−109 13.38 1.04 (1–1.08) 6.2 × 10−2 IMSGC/
WTCCC2
[25]
CYP24A1 20 rs6013897 A 0.19 −0.027 6.0 × 10−10 3.13 1.07 (1.03–1.11)e 1.7 × 10−3 IMSGC/
WTCCC2
[25]
aEffect on multiply adjusted natural-log-transformed 25OHD level in the CaMos cohort.
bp-Values derived from SUNLIGHT.
cF-statistic derived from multiply adjusted natural-log-transformed 25OHD level in the CaMos cohort.
dSNP rs12785878 was not available for MS data. Therefore SNP rs4944958 was used as a proxy (r2 between these two SNPs = 1.0).
eSNP rs6013897 was not available for MS data. Therefore SNP rs17217119 was used as a proxy (r2 between these two SNPs = 1.0).
doi:10.1371/journal.pmed.1001866.t001
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Mendelian Randomization Analysis for the Association of 25OHD with
Multiple Sclerosis Risk
In order to estimate the association of genetically lowered 25OHD with MS, we used a fixed-
effects model in which all four 25OHD-decreasing alleles of the MR set were included. We
observed that each 1-SD decrease in natural-log-transformed 25OHD level was associated with
an increased risk of MS (OR = 2.02, 95% CI: 1.65–2.46, p = 7.72 × 10−12) (Table 2; Fig 4). Given
that the I2 estimate of heterogeneity was somewhat increased (I2 = 63%, 95% CI: 0%–88%), we
also undertook random-effects meta-analysis, which generated similar findings (OR = 2.07,
95% CI: 1.45–2.96, p = 5.74 × 10−5) (Table 2; S1 Fig). We note that since our model included
only four SNPs, the 95% CIs of the I2 statistic are wide, and consequently heterogeneity cannot
be accurately measured using this parameter. In addition, to address the potential effects of
population stratification and pleiotropy, we undertook a sensitivity analysis excluding the
rs12785878 SNP (DHCR7). Despite removal of this variant, we observed a clear association
of genetically lowered 25OHD level with the risk of MS (OR = 1.72, 95% CI: 1.34–2.21,
p = 2.28 × 10−5; I2 = 47%, 95% CI: 0%–85%) (Table 3; Fig 5), which remained significant using
a random-effects meta-analysis (OR = 1.82, 95% CI: 1.24–2.67, p = 2.13 × 10−3; I2 = 47%, 95%
CI: 0%–85%) (Table 3; S2 Fig). Removal of the rs2282679 SNP (GC), which may possibly be
influenced by pleiotropy, did not influence the MR results using a fixed-effects or random-
effects model (OR = 2.17, 95% CI: 1.73–2.72, p = 1.7 × 10−11; I2 = 67%, 95% CI: 0%–91%; and
OR = 2.32, 95% CI: 1.49–3.61, p = 1.8 × 10−4; I2 = 67%, 95% CI: 0%–90%, respectively) (S3 and
S4 Figs). To further assess the effect of the independent vitamin D pathways on the risk of MS,
we analyzed SNPs near genes implicated in 25OHD synthesis (DHCR7 and CYP2R1) and
Fig 3. 25OHD level by number of 25OHD-decreasing alleles in the CaMos cohort.Here we show the
box-plot of natural-log-transformed 25OHD by the count of 25OHD-decreasing alleles in the CaMos
population. A count of zero represents individuals with no 25OHD-decreasing alleles (or homozygous at each
loci for the 25OHD-increasing allele), and a count of six represents an individual with six 25OHD-decreasing
alleles. No individuals with a count of seven or more 25OHD-decreasing alleles were observed in this cohort.
The center line and error bars represent the mean level of natural-log-transformed 25OHD and its 95% CI for
each respective allele count. Note a negative trend between allele count and mean natural-log-transformed
25OHD.
doi:10.1371/journal.pmed.1001866.g003
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metabolism (GC and CYP24A1) separately and found that both strongly associated with
increased risk of MS (Table 4; S5 and S6 Figs).
The clinical equivalences of a 1-SD increase in natural-log-transformed 25OHD for the
thresholds for vitamin D deficiency (<25 nmol/l), vitamin D insufficiency (<50 nmol/l), and
vitamin D sufficiency (>75 nmol/l) are shown in Table 5. We observed that for individuals at
the threshold for vitamin D deficiency (25OHD = 25 nmol/l), an increase in 25OHD level to
36.9 nmol/l would be required to decrease the odds of MS by 50%, while for individuals at the
thresholds for vitamin D insufficiency (25OHD = 50 nmol/l) and vitamin D sufficiency
(25OHD = 75 nmol/l), an increase in 25OHD level to 73.7 nmol/l and 110.6 nmol/l, respec-
tively, would similarly be required.
Discussion
Using summary-level data for MS and 25OHD levels from large European populations, our
study demonstrated that a genetic decrease in natural-log-transformed 25OHD by 1 SD was
associated with a 2-fold increase in risk of MS, providing strong evidence in support of a causal
role of vitamin D in MS susceptibility. These findings are consistent with evidence from obser-
vational studies that have demonstrated that low vitamin D levels influence risk of MS and also
reflect findings from functional studies that have implicated vitamin D as an important regula-
tor in the expression of MHC class II genes [47,48]. This evidence provides rationale to further
investigate whether vitamin D supplementation may reduce MS susceptibility in those most at
risk.
Table 2. Mendelian randomization estimate of the association of decreased 25OHDwith the risk of
multiple sclerosis.
Model OR (95% CI)a p-Value I2 (95% CI)
Fixed effects 2.02 (1.65–2.46) 7.72 × 10−12 63% (0%–88%)
Random effects 2.07 (1.45–2.96) 5.74 × 10−5 63% (0%–88%)
aOR is expressed as the odds of MS for a 1-SD decrease in natural-log-transformed 25OHD level.
doi:10.1371/journal.pmed.1001866.t002
Fig 4. Mendelian randomization estimate of the association of 25OHD level with risk of multiple sclerosis. Estimates obtained using a fixed-effects
model.
doi:10.1371/journal.pmed.1001866.g004
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The identification of vitamin D as a causal susceptibility factor for MS may have important
public health implications since vitamin D insufficiency is common [13,14], and vitamin D
supplementation is both relatively safe and cost-effective [35]. The importance of these find-
ings may be magnified in high-latitude countries, which have disproportionately higher rates
of MS and also higher rates of vitamin D insufficiency.
A reasonable first step to understanding the role of vitamin D therapy in delaying the onset
or severity of MS would be to treat vitamin D insufficiency in those most at risk of developing
MS. MS is often preceded by clinically isolated syndrome, which is a first clinical episode com-
patible with MS, often accompanied by lesions on magnetic resonance imaging [44], thereby
providing a therapeutic window and rationale for intervening with vitamin D supplementation.
Ongoing RCTs are currently assessing vitamin D supplementation for the treatment and pre-
vention of MS [49,50] and may therefore provide needed insights into the role of vitamin D
supplementation.
An important difference between MR studies and RCTs is that MR studies describe the
association of a lifetime of exposure to vitamin-D-lowering alleles in the general population,
whereas RCTs provide insights from supplementation for shorter periods in individuals at risk.
Thus, long-term RCTs may be needed to adequately assess the impact of vitamin D supple-
mentation in the prevention or treatment of MS. Lastly, MR may be an ideal study design to
understand risk factors for MS, given the long latency period between disease onset and diag-
nosis, since MR may permit the estimation of lifetime exposure to risk factors.
Our analysis has several strengths. First, by utilizing the random allocation of genetic vari-
ants, we were able to overcome potential confounding and reverse causation that may bias
Table 3. Mendelian randomization estimate of the association of decreased 25OHDwith the risk of
multiple sclerosis excluding theDHCR7 locus.
Model OR (95% CI)a p-Value I2 (95% CI)
Fixed effects 1.72 (1.34–2.21) 2.28 × 10−5 47% (0%–85%)
Random effects 1.82 (1.24–2.67) 2.13 × 10−3 47% (0%–85%)
aOR is expressed as the odds of MS for a 1-SD decrease in natural-log-transformed 25OHD level.
doi:10.1371/journal.pmed.1001866.t003
Fig 5. Mendelian randomization estimate of the association of 25OHD level with risk of multiple sclerosis excluding theDHCR7 locus. Estimates
obtained using a fixed-effects model.
doi:10.1371/journal.pmed.1001866.g005
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estimates from observational studies. Second, using data from the largest genetic consortia for
25OHD level (n = 33,996) and MS risk (up to 14,498 cases and 24,091 controls) has enabled us
to more precisely test our study hypothesis than if we had used individual-level data from a
small study. Previous work has shown that using estimates from meta-analytic data for uncor-
related genetic variants is similarly efficient to using individual-level data in MR studies [29].
Lastly, the findings from this study represent the association of a lifelong exposure to reduced
vitamin D levels with MS in the general European population, and, in the absence of large-
scale, long-term RCT data, our findings provide strong evidence in support of a causal role of
low vitamin D levels in MS susceptibility.
Our study also has limitations. First, while we have provided evidence supporting a role for
vitamin D in MS susceptibility, we cannot conclude that vitamin D plays a role in disease mod-
ulation after disease onset. While MR is able to overcome the limitations that may bias observa-
tional studies, the possibility of residual pleiotropy could bias estimates in this study. However,
in this study the main findings remained robust in multiple sensitivity analyses testing the plei-
otropy assumption, thereby decreasing the probability of bias due to pleiotropy. We also note
that all four studied SNPs are located in or near 25OHD-associated genes and influence
25OHD levels through known and distinct mechanisms. Additionally, the point estimate for
each 25OHD-decreasing allele, as well as the combined 25OHD synthesis and metabolism
pathways, was independently associated with increased risk of MS. Therefore, it is unlikely that
pleiotropy strongly biased our results. Like in most MR studies, we cannot directly assess
whether canalization, which is defined as compensatory feedback interactions, may have influ-
enced our results [15,51,52]. However, since canalization assumes that other physiological
mechanisms may attenuate the effect of genetically reduced 25OHD levels, such feedback inter-
actions would tend to bias results toward the null. In contrast, our study has generated results
that are very distinct from the null.
MR analyses using DHCR7, GC, CYP24A1, and CYP2R1 as instruments have been per-
formed in the past [53–57]. We and others recently provided evidence fromMR that low
Table 4. Mendelian randomization estimate of the association of decreased 25OHDwith the risk of
multiple sclerosis stratified by SNPs near genes involved in 25OHD synthesis versusmetabolism
using a fixed-effects model.
Model OR (95% CI)a p-Value
25OHD synthesis 2.08 (1.64–2.63) 1.1 × 10−9
25OHD metabolism 1.86 (1.26–2.74) 1.7 × 10−3
aOR is expressed as the odds of MS for a 1-SD decrease in natural-log-transformed 25OHD level. Note
that the 95% CI for the I2 cannot be properly estimated given that there are only two SNPs per model.
doi:10.1371/journal.pmed.1001866.t004
Table 5. Clinical equivalence of a 1-SD natural-log increase in 25OHD for various vitamin D
thresholds.
Clinically Relevant 25OHD Threshold 25OHD Level Required to Decrease Odds of MS by 50%a
Vitamin D deﬁcient (25 nmol/l) 36.86 nmol/l
Vitamin D insufﬁcient (50 nmol/l) 73.72 nmol/l
Vitamin D sufﬁcient (75 nmol/l) 110.6 nmol/l
aExpressed as the equivalent of a natural-log-transformed SD increase in 25OHD on the nanomoles/liter
scale.
doi:10.1371/journal.pmed.1001866.t005
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vitamin D levels do not increase insulin resistance [53] or the risk of type 2 diabetes [53,54] or
coronary heart disease [53], but do increase the risk of type 1 diabetes [55] and possibly blood
pressure [56]. Interestingly, MR has shown that 25OHD levels are directly influenced by BMI,
and converse effects are likely to be small [57]. Thus, while observational associations between
25OHD and two autoimmune conditions—type 1 diabetes and nowMS—have been supported
by genetic evidence, associations with cardio-metabolic outcomes have not been supported
thus far.
In conclusion, using data from the largest existing genetic consortia, we demonstrate that
genetically lowered 25OHD level is associated with an increase in the risk of MS in people of
European descent. These findings provide rationale for further investigating the potential ther-
apeutic benefits of vitamin D supplementation in preventing the onset and progression of MS.
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Editors' Summary
Background
Multiple sclerosis (MS) is a debilitating neurological disorder that affects the nerves in the
brain and spinal cord and that usually presents between the ages of 20 and 40 years. It is
an autoimmune disease—a disease in which the body’s immune system attacks healthy tis-
sues. In the case of MS, the immune system attacks myelin, the fatty tissue that forms an
insulating sheath around nerves fibers. Multiple areas of scarring (sclerosis) in the myelin
are produced by immune attack, and the damage slows down or blocks the transmission
of electrical signals along the nerves to and from the brain and causes symptoms such as
loss of vision, muscle stiffness, and daytime fatigue. For most affected individuals, MS ini-
tially follows a relapsing–remitting course characterized by periods lasting days or weeks
during which symptoms flare up, followed by periods during which symptoms becomes
milder or disappear. Half of people with relapsing–remitting MS eventually develop sec-
ondary progressive MS, in which their symptoms inexorably worsen. There is currently no
cure for MS, but some treatments can relieve its symptoms or reduce the number of
relapses.
WhyWas This Study Done?
Why the immune system attacks myelin to cause MS is unclear but probably involves both
genetic and environmental risk factors. One potential environmental risk factor is reduced
levels of vitamin D. Circulating levels of 25-hydroxyvitamin D (25OHD; the clinical deter-
minant of vitamin D status) are determined in part by exposure to sunlight, and MS is
more common at higher latitudes, where exposure to sunlight is decreased. Other epidemi-
ological studies (investigations that examine disease patterns in populations) also suggest
an association between lower vitamin D level and an increased risk of MS but cannot
prove that a decreased vitamin D level actually causes MS. Individuals who develop MS
might share another unknown characteristic that increases their risk of MS (confounding),
or individuals who have MS might spend less time outdoors and, as a result, have lower
circulating vitamin D levels (reverse causation). It is important to know whether a
decreased vitamin D level increases the risk of MS because vitamin D insufficiency is
becoming increasingly common. Here, the researchers undertake a Mendelian randomiza-
tion study to determine whether circulating vitamin D level has a causal effect on MS sus-
ceptibility. Because gene variants are inherited randomly, they are not prone to
confounding. Reverse causation is also prevented since MS does not change genetic vari-
ants. So, if vitamin D level actually affects MS risk, genetic variants that affect vitamin D
level should be associated with altered susceptibility to MS.
What Did the Researchers Do and Find?
The researchers first ascertained the effect on 25OHD level among participants in the
Canadian Multicentre Osteoporosis Study of four single nucleotide polymorphisms
(SNPs, a type of genetic variant) that were associated with 25OHD level in a genome-wide
association study (SUNLIGHT). Each of the SNPs explained an important proportion of
the population-level variance in 25OHD level in the Canadian Multicentre Osteoporosis
Study. The researchers then used the SNPs to examine whether there was an association
between genetically reduced 25OHD level and susceptibility to MS among participants in
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the International Multiple Sclerosis Genetics Consortium study, a genome-wide associa-
tion study involving up to 14,498 people with MS and 24,091 healthy controls. They found
that a genetic decrease in the natural-log-transformed 25OHD level by one standard devi-
ation was associated with a 2-fold increased risk of MS. In practical terms, this finding
means that increasing an individual’s circulating 25OHD level by approximately 1.5-fold
decreases their odds of developing MS by 50%.
What Do These Findings Mean?
These findings show that, among the participants of the International Multiple Sclerosis
Genetics Consortium study, all of whom were of European ancestry, genetically lowered
25OHD level was strongly associated with increased susceptibility to MS. Although the
Mendelian randomization approach used here largely avoids the possibility of confound-
ing or reverse causation, the reliability of these findings may be limited by some of the
assumptions made by the researchers during their analysis. Moreover, although these find-
ings support a role for vitamin D in MS susceptibility, they provide no information about
whether vitamin D modulates the course of MS after its onset, and they may not apply to
people of non-European ancestry. Nevertheless, these findings provide a strong rationale
for undertaking randomized controlled trials to investigate whether vitamin D supplemen-
tation can prevent the onset and/or progression of MS.
Additional Information
This list of resources contains links that can be accessed when viewing the PDF on a device
or via the online version of the article at http://dx.doi.org/10.1371/journal.pmed.1001866.
• The UK National Health Service Choices website provides information about multiple
sclerosis, including personal stories, and information about vitamin D and how to get
vitamin D from sunlight; A “Behind the Headlines” article examines health claims made
for vitamin D
• The US National Institute of Neurological Disorders and Stroke provides information
about multiple sclerosis and links to MS societies
• The National Multiple Sclerosis Society, a US not-for-profit organization, provides
information about all aspects of MS, including information about vitamin D and MS
and personal stories about MS
• The Multiple Sclerosis Society, a UK not-for-profit organization, also provides informa-
tion about MS for patients, carers, and professionals in several languages, including
news about the latest research, personal blogs, and forums
• The US Office of Dietary Supplements provides information about vitamin D (in
English and Spanish)
• MedlinePlus has links to further information about multiple sclerosis and vitamin D (in
English and Spanish)
• Wikipedia has a page on Mendelian randomization (note: Wikipedia is a free online
encyclopedia that anyone can edit; available in several languages)
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